Pluri logo

PluriNASDAQ: PLUR

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

30 June 2003

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$27.08 M
-72%vs. 3y high
28%vs. sector
-vs. 3y high
-vs. sector
282.06
-27%vs. 3y high
100%vs. sector
-72%vs. 3y high
93%vs. sector

Price

after hours | Mon, 04 Nov 2024 22:15:21 GMT
$4.95-$0.04(-0.80%)

Dividend

No data over the past 3 years
$96.00 K-$5.73 M

Analysts recommendations

Institutional Ownership

PLUR Latest News

Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates
globenewswire.com18 July 2024 Sentiment: POSITIVE

PluriCDMO™, the Company's contract development and manufacturing organization, recognized as a leading manufacturing partner offering scalability and mass scale production to a growing number of innovative life science companies PluriCDMO™, the Company's contract development and manufacturing organization, recognized as a leading manufacturing partner offering scalability and mass scale production to a growing number of innovative life science companies

Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges
globenewswire.com18 June 2024 Sentiment: POSITIVE

HAIFA, Israel, June 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote global wellbeing and sustainability, today announced strategic investments in Pluri's subsidiary, Ever After Foods Ltd. (“Ever After Foods”), which offers a cutting-edge technology platform to produce cultivated food with unmatched, cost-efficient scalability. Ever After Foods is Pluri's majority-owned joint venture with Israeli food giant Tnuva Food-Tech Incubator (2019), L.P. (“Tnuva”), and has exclusive licensing rights to use Pluri's technology and intellectual property to develop, manufacture and commercialize cultivated meat. The $10 million funding round will propel Ever After Foods' cost-advantageous and scalable technology platform, positioning it as a leading technology enabler.

Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale
globenewswire.com20 May 2024 Sentiment: POSITIVE

HAIFA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote global wellbeing and sustainability, today announced a strategic collaboration with Wilk Technologies Ltd. (TASE: WILK) (“Wilk Technologies” or “Wilk”), a developer of authentic, cell-cultured human and animal milk components. By combining Pluri's cutting-edge 3D cell-expansion technology with Wilk's expertise in developing cultured human breast and animal milk products, the strategic collaboration will use the components of breast milk to develop a unique medical food intended for the elderly on a commercial scale.

Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
GlobeNewsWire28 March 2024 Sentiment: POSITIVE

Pluri's business verticals leverage Company's world-leading 3D cell expansion know-how, IP, and manufacturing facility to drive revenue and bring innovative cell-based solutions to numerous industries Pluri's business verticals leverage Company's world-leading 3D cell expansion know-how, IP, and manufacturing facility to drive revenue and bring innovative cell-based solutions to numerous industries

What type of business is Pluri?

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and a novel immunotherapy platform. The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to COVID-19, peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, is composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and phase I trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It also offers cell manufacturing services; cell-based coffee; and develops and commercializes cultivated meat products. The company operates in the field of regenerative medicine, food-tech, CDMO, and agtech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

What sector is Pluri in?

Pluri is in the Healthcare sector

What industry is Pluri in?

Pluri is in the Biotechnology industry

What country is Pluri from?

Pluri is headquartered in Israel

When did Pluri go public?

Pluri initial public offering (IPO) was on 30 June 2003

What is Pluri website?

https://www.pluri-biotech.com

Is Pluri in the S&P 500?

No, Pluri is not included in the S&P 500 index

Is Pluri in the NASDAQ 100?

No, Pluri is not included in the NASDAQ 100 index

Is Pluri in the Dow Jones?

No, Pluri is not included in the Dow Jones index

When was Pluri the previous earnings report?

No data

When does Pluri earnings report?

The next expected earnings date for Pluri is 13 November 2024